Dr. Nina Niu Sanford (@NiuSanford) ranks #9 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 24 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: CRITICS-II, ABC-HCC. CMS Open Payments lists $2,350 in 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 2 trials discussed by name
- GI Cancer: US #9 · 24 physicians engaged
- Leading physician voice: #1 of 7 physicians on ABC-HCC; #3 of 7 physicians on CRITICS-II
- CMS Open Payments lists $2,350 in 2025 general payments.
This Month
What Dr. Nina Niu Sanford has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Dr. Nina Niu Sanford
Physicians who reposted Dr. Nina Niu Sanford’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GI Cancer | #9 | — | 24 | 37 | Full ranking |
Trials Dr. Nina Niu Sanford Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| CRITICS-II | 2 | #3 of 7 | Jan 9, 2026 |
| ABC-HCC | 1 | #1 of 7 | Jan 9, 2026 |
Dr. Nina Niu Sanford on CRITICS-II
Here is a great trial already in progress building off MATTERHORN & CRITICS-II (presented today)! Japanese EPOC2031 Ph2: TNT for resectable GEJ -FLOT + pembro + short course RT (25 Gy/5fx) -1 endpt: EFS -Key 2nd endpts: organ pres & QOL #GI26 @OncoAlert https://t.co/AuBHqKJthB https://t.co/fjpn7oLMfW
CRITICS-II: multicenter Ph2 RCT in resectable gastric ca showing preop chemo (DOC) + CRT improved 1-yr EFS & pCR (20%) v CRT or chemo alone. But w D-FLOT now SOC, q’s are: 1. Could adding pre-op chemoRT to D-FLOT further improve pCR enabling organ pres option? #GI26 🧵1/2 https://t.co/XM2wkY8HiO
Dr. Nina Niu Sanford on ABC-HCC
ABC-HCC: Ph3 atezo/bev v TACE (BCLC B) Atezo/bev improved TTFS (HR 0.54) While endpt does penalize LRT, reinforces TACE not curative - diminishing returns & risk of liver decomp over time. Supports shift to earlier systemic & questions if TACE should remain 1L #GI26 @OncoAlert https://t.co/3rckFa4C5b
Dr. Nina Niu Sanford’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Increased toxicity (& cost) w TACE/systemic combo, so why not give drug(s) at progression? No demonstrated OS benefit yet w upfront. Also given TACE lower local control, PFS benefit (3-5 mo) from systemic addition might partly reflect compensation for local failures. @OncoAlert https://t.co/XFZiJyhQYS
This WSJ article getting much attention but all studies observational. Though signal appears to be consistent & ~42 (!!) #ASCO26 abstracts also reporting association b/w GLP-1 & better cancer outcomes. Hope for RCTs to clarify true anticancer biology vs. confounding. @OncoAlert https://t.co/vV97Rt7VKA https://t.co/zRV07AKyAY
Impressive daraxonrasib data. From RT standpt, if RAS inhibition meaningfully prolongs dz control, local progression = more relevant Future trials should test consolidative ablative RT in pts responding to darax (potentially leveraging RAS-mediated radiosens) #ASCO26 @OncoAlert https://t.co/FPh55csgq5
Catching up w my coresident @dbittermanmd at #ASCO26! Big congrats to Danielle on her new job - Head of AI at AstraZeneca! https://t.co/YmtKULuplQ
Industry Payments
CMS Open Payments · 2025 general payments
$2,350 across 2 payments